Guardian Pharmacy Services (NYSE:GRDN) Reaches New 1-Year High – What’s Next?

Guardian Pharmacy Services, Inc. (NYSE:GRDN)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $41.79 and last traded at $41.58, with a volume of 124747 shares traded. The stock had previously closed at $40.80.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on GRDN. Bank of America assumed coverage on Guardian Pharmacy Services in a report on Monday, April 27th. They issued a “buy” rating and a $42.00 target price on the stock. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. UBS Group restated a “buy” rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Finally, Jefferies Financial Group initiated coverage on shares of Guardian Pharmacy Services in a report on Monday, March 30th. They set a “buy” rating and a $44.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Guardian Pharmacy Services Trading Down 0.0%

The firm has a market capitalization of $2.03 billion, a PE ratio of 49.14, a price-to-earnings-growth ratio of 2.57 and a beta of 0.08. The business has a 50-day moving average of $37.57 and a 200 day moving average of $33.54.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. The business had revenue of $336.60 million during the quarter, compared to analyst estimates of $329.89 million. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.Guardian Pharmacy Services’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.22 EPS. On average, sell-side analysts expect that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John Ackerman sold 1,103,364 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $32,747,843.52. Following the completion of the sale, the director directly owned 345,123 shares of the company’s stock, valued at approximately $10,243,250.64. This represents a 76.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kendall Forbes sold 346,672 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $10,289,224.96. Following the completion of the sale, the insider directly owned 453,256 shares of the company’s stock, valued at $13,452,638.08. The trade was a 43.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 9,726,405 shares of company stock worth $288,679,700 in the last three months. 32.96% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Guardian Pharmacy Services

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in Guardian Pharmacy Services by 86.1% during the first quarter. Bank of America Corp DE now owns 128,048 shares of the company’s stock valued at $4,822,000 after buying an additional 59,245 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Guardian Pharmacy Services by 67.4% in the first quarter. The Manufacturers Life Insurance Company now owns 11,820 shares of the company’s stock valued at $445,000 after acquiring an additional 4,761 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Guardian Pharmacy Services by 79.1% in the first quarter. Arrowstreet Capital Limited Partnership now owns 38,185 shares of the company’s stock valued at $1,438,000 after acquiring an additional 16,866 shares during the last quarter. Sei Investments Co. boosted its stake in Guardian Pharmacy Services by 40.5% in the first quarter. Sei Investments Co. now owns 358,181 shares of the company’s stock valued at $13,489,000 after acquiring an additional 103,177 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in Guardian Pharmacy Services in the first quarter valued at about $3,528,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.